The Valley Desk

NCT04128696 · Interventional trial

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Overall registry status Terminated

Phase 3

Conditions Neoplasms, Head and Neck

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov